Pembrolizumab shows promise in treatment of mesothelioma

Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania. The study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease. …read more

Source: EurekAlert

(Visited 5 times, 1 visits today)

Popular Posts